Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring

FA Corporation

Status: Not yet enrolling

Conditions: Rhytids; Skin Laxity

Treatments: Device: 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical)

Study type: Interventional

Funder types: Industry

Identifiers

NCT07254884

UC 28-2025

Details and patient eligibility

About

The primary objective of this clinical trial is to evaluate the safety and effectiveness of the 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical) for non-invasive dermatological aesthetic treatment of three facial regions: eyebrow lift (Region 1), submental tissue lift (Region 2), and improvement of rhytids and skin laxity in the cheeks, midface, and jawline (Region 3).

Enrollment: 40 estimated patients

Sex: All

Ages: 45 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Fitzpatrick skin type I-VI
• Male or female
• Subjects must be between 45 and 85 years of age
• Subjects must have the ability to receive two and up to three full face and upper neck resurfacing laser treatments (pending PI discretion) with desire to lift facial lax skin, submental and/or to lift the eyebrow area and/or improve facial wrinkles appearance
• Subjects must read, understand, and sign the Informed Consent Form
• Subjects must be willing and able to comply with all follow-up visit requirements
• Subjects must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator
• Subjects must be rated as (2) Moderate Sagging to (4) Very Severe Sagging based on the Merz Scale: Jawline at Rest
• Subject identified as an appropriate candidate for study treatment based on principal investigator's opinion
• Subjects of childbearing potential have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study

Exclusion criteria

• Subjects must not have active localized or systemic infections
• Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atopic dermatitis or immunologic abnormalities such as vitiligo
• Subjects must not be current smoker or have significant history of smoking
• Subjects must not have had treatments with systemic steroids or systemic retinoids in the 4-months prior to enrollment
• Subjects must not have had treatments with 5FU, diclofenac, imiquimod or PDT within 1-month prior to enrollment
• Subjects must not have severe or cystic facial acne; currently taking Accutane or have taken Accutane within the last 1-month
• Subjects must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications
• Subjects must not have had previous surgery and/or fat transfer in the treatment area within the last 6-months
• Subject must not have had injectable soft tissue fillers within the last 12 months in the treatment area
• Subject must not have had Poly-L-Lactic acid (PLLA) fillers within the last 2 years in the treatment area
• Subject must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area
• Subjects must not have had neurotoxins within the last 4-months in the treatment area
• Subject must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12-months
• Subject must not have had a pulse dye or vascular laser, non-ablative laser, microneedling or RF microneedling treatments in the treatment area within the last 3-months
• Subject must not have had an ultrasound treatment such as HIFU, monopolar RF energy-based devices, ablative laser treatments in the treatment area within the last 6-months
• Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia
• Subject must not have active sunburn or excessively tanned skin
• Subjects must not be pregnant or planning to become pregnant, have given birth less than 3 months ago, and/or breastfeeding during the study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Laser Treatment Arm

Experimental group

Description:

Enrolled subjects will receive a series of two with an optional third 2,910 nm Fiber Laser treatments using fractional ablative resurfacing modes, laser-coring and full ablation addressing the full face and upper neck

Treatment:

Device: 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical)